1. Baxter GF and Ferdinandy P. Delayed preconditioning
of myocardium: current perspectives. Basic Res Cardiol 96: 329-344,
2001.
2. Csonka C, Csont T, Onody A and Ferdinandy P. Preconditioning
decreases ischemia/reperfusion-induced peroxynitrite formation. Biochem
Biophys Res Commun 285: 1217-1219, 2001.
3. Csonka C, Szilvassy Z, Pali T, Blasig IE, Tosaki A, Schulz R and
Ferdinandy P. Classic preconditioning decreases the harmful
accumulation of nitric oxide during ischemia and reperfusion in rat
hearts. Circulation 100: 2260-2266, 1999.
4. Ferdinandy P. Myocardial ischaemia/reperfusion injury and
preconditioning: effects of hypercholesterolaemia/hyperlipidaemia. Br J
Pharmacol 138: 283-285, 2003.
5. Ferdinandy P and Schulz R. Nitric oxide, superoxide, and
peroxynitrite in myocardial ischaemia-reperfusion injury and
preconditioning. Br J Pharmacol 138: 532-543, 2003.
6.Ferdinandy P, Schulz R, Baxter GF.
Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
Pharmacol Rev. 2007 Dec;59(4):418-58.
7. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R and Ferdinandy P.
Hyperlipidemia attenuates the infarct size-limiting effect of ischemic
preconditioning: role of matrix metalloproteinase-2 inhibition. J
Pharmacol Exp Ther 316: 154-161, 2007.
8. Lalu M, Csonka C, Giricz Z, Csont T, Schulz R and Ferdinandy P.
Preconditioning decreases ischemia/reperfusion-induced release and
activation of matrix metalloproteinase-2. Biochem Biophys Res Commun
296: 937-941, 2002.
9. Onody A, Csonka C, Giricz Z and Ferdinandy P. Hyperlipidemia
induced by a cholesterol-rich diet leads to enhanced peroxynitrite
formation in rat hearts. Cardiovasc Res 58: 663-670, 2003.
10. Puskas LG, Nagy ZB, Giricz Z, Onody A, Csonka C, Kitajka K, Hackler
L, Jr., Zvara A and Ferdinandy P. Cholesterol diet-induced
hyperlipidemia influences gene expression pattern of rat hearts: a DNA
microarray study. FEBS Lett 562: 99-104, 2004.
11. Qun GC, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy
P and Schulz R. Matrix metalloproteinase-2 mediates cytokine-induced
myocardial contractile dysfunction. Cardiovasc Res 57: 426-433, 2003.
12. György Dormán, Katalin Kocsis-Szommer, Cesare Spadoni and Péter
Ferdinandy, MMP Inhibitors in Cardiac Diseases: An Update, Recent
Patents on Cardiovascular Drug Discovery, 2007, 2, 707-723
13. Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T, Ferdinandy P.
Matrix metalloproteinase activity assays: Importance of zymography.
J Pharmacol Toxicol Methods. 2010 Mar-Apr;61(2):205-9. Epub 2010 Feb 20.
